23 June - “Cardiovascular disease is the leading cause of death for people with type 2 diabetes,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “There remains an unmet medical need to further reduce cardiovascular risk in people with type 2 diabetes and we are very pleased that the CHMP has recommended the Victoza® label update based on the LEADER trial.”
22 June - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use, under the European Medicines Agency (EMA), has endorsed an update of the EU label for Saxenda®. This update is based on the results from the LEADER trial which investigated the long-term effects of Victoza® in people with type 2 diabetes and established cardiovascular disease.
“We are very pleased that data from the LEADER trial has been included in the Saxenda® label in Europe,” said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk. “The LEADER trial showed that liraglutide is associated with significant cardiovascular risk reduction in people with type 2 diabetes. This is an important development for people with obesity in Europe living with weight-related comorbidities such as cardiovascular disease.”
21 June - the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US FDA completed its meeting regarding the supplemental New Drug Application for inclusion of the data from the cardiovascular outcomes trial LEADER in the label for.
The discussions at the meeting were based on data from the LEADER trial, (more than 9,300 people with type 2 diabetes and high risk of major cardiovascular events). The Advisory Committee voted 19-0 in favour of Victoza® on the question: “Do the results of LEADER establish that use of Victoza® in patients with type 2 diabetes is not associated with excess cardiovascular risk?” The Committee voted 17-2 in favour of Victoza® on the question: “Does the LEADER trial provide the substantial evidence needed to establish that Victoza® reduces cardiovascular risk in patients with type 2 diabetes?”
“Cardiovascular disease is the number one cause of death for people with type 2 diabetes,” said Mads Krogsgaard Thomsen, EVP and chief science officer of Novo Nordisk. “With the positive vote today, we are excited to be one step closer towards a cardiovascular indication for Victoza® to reduce the risk of cardiovascular events in people with type 2 diabetes".
13 June - The Novo Nordisk press briefing at the 77th Scientific Sessions of the American Diabetes Association (ADA) completed with the following three announcements:
With millions displaced by war, business has a key role in helping refugees integrate, contribute and flourish in society. Each individual you meet has their own personal backstory of despair and upheaval. Days on end spent on an over-crowded boat, bobbing on the Mediterranean. Families fragmented and dispersed. Careers and livelihoods abruptly curtailed.
Imagine that you perceive the noise level in the canteen as 100 times louder, and that even minor changes in your daily life cause you to lose your overview. Such is life for 28-year-old Louise Wille, who has Asperger’s and ADHD.
Novo Nordisk and Glooko will work together to deliver jointly-developed and branded digital health solutions for people with diabetes. The companies aim to deliver personalised, digital services to support people with diabetes in areas including treatment adherence and blood glucose management. Read all the details
31 May - The US FDA has today approved the Biologics License Application for REBINYN® for the treatment of adults and children with haemophilia B. “We are excited about the approval of REBINYN® in the US, and we consider it an important expansion of the treatment options for patients with haemophilia B”, said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “We are confident that REBINYN® will become an important tool for physicians to help patients manage their bleeds.”
Novo Nordisk expects to launch REBINYN® in the US in the first half of 2018.
30 January - University of Oxford and Novo Nordisk has announced a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk and University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes. Sir John Bell, Regius Professor of Medicine, University of Oxford, said: “We see the collaboration with Novo Nordisk as an outstanding opportunity to mix competence embedded at our campus with Novo Nordisk’s groundbreaking research and results in diabetes. This collaboration underlines the importance of shared research and cutting-edge science across boundaries". The Novo Nordisk Research Centre Oxford will employ up to 100 Novo Nordisk researchers.
22 September - Access to reliable and affordable supplies of insulin is a challenge for many in the poorest nations in the world. Lars Rebien Sørensen has pledged to extend the current programme from 2001 and expand Novo Nordisk's commitment to supply human insulin at fixed low prices to the Least Developed Countries and low-income nations; the programme will now be extended to cover selected organisations providing relief in humanitarian situations.
Read all the details about Novo Nordisk's programme on access to insulin
Read about former CEO Lars Rebien Sørensen's reflections on 2016 and present CEO Lars Fruergaard Jørgensen's thoughts about the road ahead for Novo Nordisk and much more in the Annual Report 2016
Read about: Risky business! - What are the most pressing dilemmas businesses will face in 2017? - Navigating in the eye of the storm and - How long is long-term commitment? - and much more
Get an instant impression of what Novo Nordisk is about, see the numbers and read about partnership activities that drive change.
The view on obesity is slowly changing, but there are still many myths about the disease that all contribute to creating barriers for proper treatment.